论文部分内容阅读
应用免疫组织化学LSAB法检测P16蛋白在胰腺癌中的表达。结果显示，47例胰腺癌P16蛋白表达阳性率为55．3％（26／47）；其阳性率与患者性别、年龄、肿瘤大小，病理学类型及组织学分级无关；而与胰腺癌临床分期和患者1年生存率明显相关（P<0．05）。表明P16基因缺失或突变在胰腺癌发生发展的后期发挥重要作用；P16蛋白低表达者预后差。因此P16蛋白可作为胰腺癌的分子生物学标志。
The expression of P16 protein in pancreatic cancer was detected by LSAB immunohistochemistry. The results showed that the positive rate of P16 protein expression in 47 cases of pancreatic cancer was 55.3% (26/47); the positive rate was not related to gender, age, tumor size, pathological type, and histological grade; however, it was related to the clinical stage of pancreatic cancer. The 1-year survival rate was significantly related to the patient (P<0.05). It is suggested that the deletion or mutation of P16 gene plays an important role in the later stage of the development of pancreatic cancer; the poor expression of P16 protein has a poor prognosis. Therefore, P16 protein can be used as a molecular biological marker of pancreatic cancer.